[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Samuel Kintz, President, CEO and Director of Enliven Therapeutics (ELVN), reported a sale of 2,800 shares of common stock on 09/23/2025 at a price of $20.03 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024. After the transaction, the reporting person beneficially owns 919,092 shares indirectly through The Kintz & Egan Trust dated March 30, 2019, for which he serves as trustee. The Form 4 was signed by Ben Hohl by power of attorney on 09/25/2025.

Positive

• Sale executed under a Rule 10b5-1 trading plan, indicating the transaction was pre-planned and reduces insider timing concerns.
• Substantial remaining beneficial ownership of 919,092 shares held indirectly via The Kintz & Egan Trust, showing continued alignment with shareholders.
• Clear role disclosure: Reporting person identified as President, CEO and Director, improving transparency.

Negative

• Insider sale reported of 2,800 shares, which some investors may view negatively despite being small relative to total holdings.
• Shares held indirectly through a trust could limit visibility into direct economic incentives compared with direct holdings.

Insights

Financial Analyst

TL;DR: Insider sold a small amount under a pre-established 10b5-1 plan while retaining a large indirect stake of 919,092 shares.

The 2,800-share sale at $20.03 appears routine and was governed by a Rule 10b5-1 plan adopted in November 2024, which reduces timing concerns about opportunistic trading. The remaining indirect ownership of 919,092 shares indicates continued alignment with shareholders. The transaction size is small relative to the reported beneficial position, suggesting limited impact on control or ownership concentration.

Corporate Governance Expert

TL;DR: Use of a documented 10b5-1 plan and trustee-held shares provide governance transparency; transaction is modest in size.

Filing shows appropriate disclosure: role of reporting person is stated, sale is disclosed with plan provenance, and indirect ownership via a family trust is identified. The power-of-attorney signature is properly noted. From a governance perspective, the disclosure meets Section 16 reporting norms and signals procedural compliance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kintz Samuel

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/23/2025		S(1)		2,800	D	$20.03	919,092	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

2. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

	/s/ Ben Hohl, by power of attorney	09/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Samuel Kintz report on Form 4 for ELVN?

He reported a sale of 2,800 shares of Enliven Therapeutics common stock on 09/23/2025 at $20.03 per share.

Was the sale part of a pre-arranged trading plan for ELVN insider Samuel Kintz?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.

How many ELVN shares does Samuel Kintz beneficially own after the reported transaction?

919,092 shares are beneficially owned following the reported transaction, held of record by The Kintz & Egan Trust dated March 30, 2019.

What is Samuel Kintz's relationship to Enliven Therapeutics (ELVN)?

He is President, Chief Executive Officer and a Director of Enliven Therapeutics, as indicated on the Form 4.

Who signed the Form 4 filing for Samuel Kintz?

The form was signed by Ben Hohl by power of attorney on 09/25/2025.